Artal Group S.A. Vigil Neuroscience, Inc. Transaction History

Artal Group S.A.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$2.51 - $4.66 $43,924 - $81,550	17,500 Added 0.97%	1,828,691 $7.31 Million
Q4 2023 Feb 09, 2024	SELL	$2.97 - $8.6 $287,923 - $833,718	-96,944 Reduced 5.08%	1,811,191 $6.12 Million
Q3 2023 Nov 13, 2023	SELL	$4.8 - $9.92 $14,668 - $30,315	-3,056 Reduced 0.16%	1,908,135 $10.3 Million
Q2 2023 Aug 11, 2023	SELL	$8.11 - $10.54 $2.69 Million - $3.5 Million	-332,161 Reduced 14.81%	1,911,191 $18 Million
Q4 2022 Feb 13, 2023	SELL	$8.74 - $15.99 $369,020 - $675,129	-42,222 Reduced 1.85%	2,243,352 $28 Million
Q3 2022 Nov 14, 2022	BUY	$2.37 - $9.61 $2.76 Million - $11.2 Million	1,164,383 Added 103.85%	2,285,574 $20.8 Million
Q1 2022 May 12, 2022	BUY	$7.03 - $17.29 $7.88 Million - $19.4 Million	1,121,191 New	1,121,191 $7.88 Million

27.9M

Ticker VIGL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 28,268,600
Market Cap $85.7M
Description
Vigil Neuroscience, Inc., a microglia-focused company, engages in the development of disease-modifying therapeutics for patients, caregivers, and families affected by rare and common neurodegenerative diseases. Its lead product candidate is VGL101, a fully human monoclonal antibody (mAb) that is designed to activate triggering receptor expressed...

Get notified when there are updates to the investment portfolio of Artal Group S.A., based on Form 13F filings with the SEC.

Stay updated on Artal Group S.A. with notifications on news.